When deciding on its company moniker in 2010, bluebird bio said the name exemplified its intent to set a bold new course for the future. The Eastern Bluebird is known to be a symbol of transition and renewal as well as a competitive and disciplined bird, it said at the time, traits that were reflected in the company’s passion for transforming the lives of patients and their families.
Flight Of The Navigator: Bluebird bio's Andrew Obenshain
The gene therapy firm is transitioning to a commercial organization
For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.
More from Outlook Archive
• By
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
• By
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
• By
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
• By
What will 2023 bring as the industry faces one of the toughest periods in the last decade? In Vivo asked three industry experts for their views.
More from Outlook
• By
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.
• By
Nine biopharma companies made 12 or more deals, with Novartis inking 21 deals and leading M&A activity. Roche, meanwhile, spent little up front but maintained a hectic pace with 12 alliances.
• By
As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.